Zum Hauptinhalt springen

Hepatitiden

04. Oktober 2023 | Hepatitiden

Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study.

Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study. Thi Thu PN, Hoang Van D, Ngo Thi Quynh M, Tran Th...

24. September 2023 | Hepatitiden

Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.

Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis. Artenie A, Stone J, Facente SN, Fraser H, Hecht J, Rhodes P, McFarland W, Wilson E, Hickman ...

13. September 2023 | Hepatitiden

Reinfection incidence and risk among people treated for recent hepatitis C virus infection: the react study.

Reinfection incidence and risk among people treated for recent hepatitis C virus infection: the react study. Martinello, Marianne; Carson, Joanne M.; Van Der Valk, Marc; Rockstroh, Jürgen K.; Ingiliz, Patrick; Hellard, Margaret; Nelson, Mark...

13. September 2023 | Hepatitiden

Global burden of liver disease: 2023 update

Global burden of liver disease: 2023 update Devarbhavi, Harshad et al. Journal of Hepatology, Volume 79, Issue 2, 516 - 537 https://www.journal-of-hepatology.eu/article/S0168-8278(23)00194-0/fulltext

13. September 2023 | Hepatitiden

Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.

Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial. Lim, AG, Aas, CF, Çağlar, ES, Vold, JH, Fadnes, LT, Vicke...

13. September 2023 | Hepatitiden

Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study.

Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study. Ilhame A, Cécile D, Camelia P, David M, Joris H, Adélaïde P, Danièle B, Patrizia C, Perrine R. Harm Reduc...

13. September 2023 | Hepatitiden

"Treated like a Human Being": perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City.

"Treated like a Human Being": perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City. Kapadia SN, Aponte-Melendez Y, Rodriguez A, Pai M, Eckhardt BJ, Marks KM, Fong C, Mate...

Weitere Beiträge ansehen

Weitere
akutelle Informationen
zu den Themengebieten